Item 2.02 Results of Operations and Financial Condition. On October 29, 2026, Omnicell, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026 and updating its guidance for the full year 2026.…
Filed Oct 29, 2026Accepted Oct 29, 2026, 6:35 AM EDTCIK 926326Accession 0000926326-26-000024
Since 1992, Omnicell has been committed to delivering innovative, outcomes-centric pharmacy and nursing solutions for all settings of care. As an intelligent medication management technology company, Omnicell empowers autonomous medication management by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that improve efficiency and enhance patient safety for healthcare facilities worldwide. Learn more at omnicell.com.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On October 29, 2026, Omnicell, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026 and updating its guidance for the full year 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.